Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Patients with acute coronary syndromes undergoing angioplasty experienced nearly 50% less bleeding at 30 days when treated with Angiox alone compared to unfractionated heparin or Lovenox plus a glycoprotein IIb/IIIa inhibitor, according to data from The Medicines Company.
Subscribe to our email newsletter
The findings were consistent in patients switched to Angiox monotherapy from unfractionated heparin or Sanofi-Aventis's Lovenox (enoxaparin). The Medicines Company recently re-acquired rights for Angiox in Europe and currently markets the product as Angiomax in the US.
Lead author of the study, Harvey White, director of Coronary Care and Cardiovascular Research at Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand, said: “The reduction in early bleeding achieved with Angiox monotherapy is particularly important, as bleeding events are commonly linked to late mortality in these patients.”